Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Urol Oncol. 2022 Apr 22;40(6):271.e9–271.e18. doi: 10.1016/j.urolonc.2022.03.016

Table 4.

UVA and MVA of CO Associated with Baseline Basophils and BLR in mHSPC.

UVA MVA
OS PFS OS PFS
HR (CI) p-value HR (CI) p-value HR (CI) p-value HR (CI) p-value
Basophils ≥ 0.1 (Above) vs. <0.1 (Below optimal cut) 3.69 (1.91–7.12) <0.001 2.39 (1.42–4.01) 0.001 3.51 (1.65–7.43) 0.001 1.88 (1.05–3.38) 0.034
BLR ≥ 0.0142 (Above) vs. < 0.0142 (Below optimal cut) 1.35 (0.73–2.50) 0.338 0.76 (0.51–1.14) 0.187 2.11 (1.09–4.10) 0.028 0.87 (0.55–1.35) 0.526

The MVA was built in Cox proportional hazard model by controlling for drug, race, age at diagnosis, disease volume, ECOG, and Gleason.

95% confidence interval

BLR = basophil-to-lymphocyte ratio